PharmaTimes October 15, 2024
Partnership to harness AI for DUB-focused preclinical programmes
Dundee-based Ubiquigent Limited and San Francisco’s Alleo Labs Corp have entered a strategic partnership to advance deubiquitinase (DUB)-focused drug discovery using AI.
The collaboration aims to combine Alleo’s AI-based platform with Ubiquigent’s expertise to speed up preclinical programmes targeting neurological diseases.
Under this partnership, Ubiquigent will gain exclusive access to Alleo’s AI software, RubDUB, to find novel DUB-modulating compounds.
These compounds are crucial for developing DUB inhibitors, DUB-targeting PROTACs, and DUB-Targeting Chimeras (DUBTACs). Meanwhile, Alleo will leverage Ubiquigent’s platforms to boost its in-house precision neuroscience programmes.
Jason Mundin, CEO of Ubiquigent, highlighted the potential of this collaboration: “The potential for the development of novel DUB-targeting therapeutics has never been greater, and this...
Today's Sponsors
Today's Sponsor